Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML).

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  1996-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0145-2126(95)00134-4PMID 8628017
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry.

  1994cited by this paper
• Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses.

  1994cited by this paper
• P‐glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival

  1994cited by this paper
• Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience.

  1994cited by this paper
• Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.

  1993cited by this paper
• Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.

  1993cited by this paper
• High-dose chemotherapy and autologous transplant with peripheral-blood stem cells.

  1993cited by this paper
• Multidrug resistance: clinical relevance in acute leukemia.

  1993cited by this paper
• Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.

  1992cited by this paper
• Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis.

  1992cited by this paper
• Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity.

  1991cited by this paper
• MDR1 gene expression and treatment outcome in acute myeloid leukemia.

  1991cited by this paper
• Expression of the multidrug resistance gene product (P‐glycoprotein) in myelodysplasia is associated with a stem cell phenotype

  1991cited by this paper
• A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia.

  1991cited by this paper
• Idarubicin (4‐demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA

  1990cited by this paper
• Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.

  1990cited by this paper
• Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies.

  1990cited by this paper
• Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem‐cell glycoprotein CD34 (My 10)

  1990cited by this paper
• AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial

  1989cited by this paper
• Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo.

  1988cited by this paper
• Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.

  1986cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models.

  2020influential citation
• Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation

  2019cites this paper
• Determination of P-Glycoprotein Expression by Flow Cytometry in Hematological Malignancies

  2016cites this paper
• Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies

  2015cites this paper
• Akute myeloische Leukämie

  2015cites this paper
• Expression of P-gp in acute myeloid leukemia and the reversal function of As2O3 on drug resistance

  2014cites this paper
• myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study cytogenetically normal patients younger than 60 years with acute markers, poor outcome, and a distinct gene-expression signature in High BAALC expression associates with other molecular prognostic

  2013cites this paper
• status at diagnosis previously untreated acute myeloid leukemia (AML), in relation to MDR1 daunorubicin and cytarabine in the treatment of elderly patients with The value of the MDR1 reversal agent PSC-833 in addition to

  2013cites this paper
• Estudo da Associação de Genes e Proteínas de Resistência a Múltiplos Fármacos (abcb1/ABCB1, abcc1/ABCC1 e lrp/LRP) com Marcadores Moleculares em Pacientes Portadores de Leucemias Agudas

  2013cites this paper
• Acute myeloid leukemia : apoptotic signalling and gene expression associated with treatment response

  2013cites this paper
• Acute myeloid leukemia - Apoptotic signalling and gene expression associated with treatment response

  2013cites this paper
• The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.

  2013cites this paper
• Evaluation of multidrug resistance in 46 newly diagnosed patients with acute leukemia

  2012cites this paper
• Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity

  2012cites this paper
• Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia.

  2010cites this paper
• Older patients with acute myeloid leukemia

  2010cites this paper
• A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.

  2009cites this paper
• Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.

  2009cites this paper
• High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.

  2008cites this paper
• Determination of P‐glycoprotein, MDR‐related protein 1, breast cancer resistance protein, and lung‐resistance protein expression in leukemic stem cells of acute myeloid leukemia

  2008cites this paper
• Expression und klinische Relevanz der Liganden für die immunregulatorischen Moleküle 4-1BB und GITR bei der Akuten Myeloischen Leukämie

  2008cites this paper
• An investigation of chemoresistance of liver cancers using the comet assay and isolated organ perfusion systems

  2008cites this paper
• Diagnostik, Klassifikation und Prognosefaktoren der akuten myeloischen Leukämie

  2007cites this paper
• Drug resistance in childhood acute myeloid leukemia.

  2007cites this paper
• [Diagnostics, classification and prognostic criteria of acute myeloid leukemia].

  2007cites this paper
• Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.

  2006cites this paper
• Acute Myeloid Leukemia and the Myelodysplastic Syndromes

  2006cites this paper
• MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia

  2005cites this paper
• Biologically targeted therapies for myelodysplastic syndromes

  2005cites this paper
• Attempts to influence the drug resistance of tumor cells in experimental system.

  2005cites this paper
• The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.

  2005cites this paper
• Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21)

  2004cites this paper
• Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome.

  2004cites this paper
• Reversal of MDR by Verapamil Analogues

  2004cites this paper
• Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies.

  2004cites this paper
• A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.

  2004cites this paper
• Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.

  2004cites this paper
• Modulation of Multidrug Resistance in Acute Myeloid Leukemia

  2003cites this paper
• Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?

  2003cites this paper
• SOLVING THE PROBLEM OF MULTIDRUG RESISTANCE: ABC TRANSPORTERS IN CLINICAL ONCOLOGY

  2003cites this paper
• Myelodysplastic syndrome.

  2003cites this paper
• Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia

  2002cites this paper
• Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome.

  2002cites this paper
• Emergence of Multidrug Resistance in Leukemia Cells During Chemotherapy: Mechanisms and Prevention

  2002cites this paper
• Towards an integrated classification of adult acute lymphoblastic leukemia.

  2002cites this paper
• MDR-1 Expression and Deletions of Chromosomes 7 and 5(Q) Separately Indicate Adverse Prognosis in AML

  2001cites this paper
• Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells.

  2001cites this paper
• Drug transporters and their role in multidrug resistance of neoplastic cells.

  2001cites this paper
• Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

  2001cites this paper
• Chemotherapy resistance in acute myeloid leukaemia.

  2001cites this paper
• The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.

  2000cites this paper
• Current Clinical Practice: Application of Resistance Reversal Agents in Hematologic Malignancies

  2000cites this paper
• Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.

  2000cites this paper
• Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome

  2000cites this paper
• A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

  2000cites this paper
• Novel mechanisms of drug resistance in leukemia

  2000cites this paper
• A Case of Acute Leukemia Remitted by Adding Cyclosporin-A Previously Failed with Induction Therapy

  2000cites this paper
• P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.

  2000cites this paper
• Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance.

  1999cites this paper
• P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia.

  1999cites this paper
• Physical mapping of a tandem duplication on the long arm of chromosome 7 associated with a multidrug resistant phenotype.

  1999cites this paper
• In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy.

  1998cites this paper
• P-glycoprotein expression and prognostic value in acute myeloid

  1998cites this paper
• AML in the Elderly: a Biologically Distinct Disease in which MDR1 Expression and Unfavorable Cytogenetics Contribute to Poor Clinical Response. Studies of the Southwest Oncology Group

  1998cites this paper
• P-glycoprotein expression and prognostic value in acute myeloid leukemia.

  1998cites this paper
• Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy

  1997cites this paper
• MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia

  1997cites this paper
• Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.

  1996cites this paper
• The value of the MDR 1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia ( AML ) , in relation to MDR 1 status at diagnosis

  year unknowncites this paper